Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With the UK's post-Brexit medical device regulatory framework continuing to evolve, manufacturers placing devices on the Great Britain market must understand the future role and responsibilities of th...
When preparing a 510(k) premarket notification for a Class II medical device, how should a sponsor strategically leverage device-specific FDA guidance documents, such as the "Guidance for the Content ...
With increased regulatory scrutiny on data protection expected to intensify by 2026, how can a non-EU-based medical device or Software as a Medical Device (SaMD) manufacturer develop a comprehensive, ...
What are the primary factors that influence the cost structure for an EU Authorized Representative (AR) service under the Medical Device Regulation (MDR), and how can non-EU manufacturers evaluate the...
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic product facilities must designate a U.S. Agent. What are the specific responsibilities and practical functions of this U.S...
With significant EU cosmetic regulatory updates anticipated through 2026, including new restrictions on substances classified as CMRs (Carcinogenic, Mutagenic, or Reprotoxic), how can a non-EU brand s...
With the introduction of the European Health Data Space (EHDS), how should a non-EU-based medical device or SaMD manufacturer strategically evaluate and select a GDPR Article 27 Representative to ensu...
While non-EU manufacturers understand that appointing an EU Authorized Representative (AR) is a mandatory requirement under the Medical Device Regulation (MDR, Regulation (EU) 2017/745), determining t...
In light of the mandatory requirement for foreign cosmetic facilities to designate a U.S. Agent under the Modernization of Cosmetics Regulation Act (MoCRA), what is a comprehensive and practical metho...
How should a medical device manufacturer, particularly one with a diverse portfolio including products like Class IIa software or Class IIb implantables, conduct due diligence when selecting a "Person...
When developing a novel Class II in-vitro diagnostic (IVD), what is the strategic framework for determining if it falls under an existing classification regulation, thereby allowing a 510(k) pathway, ...
When a non-EU medical device manufacturer plans to enter the European market, they must appoint an EU Authorized Representative (AR) to comply with the Medical Device Regulation (MDR). However, other ...
The Modernization of Cosmetics Regulation Act (MoCRA) mandates that foreign cosmetic facilities designate a U.S. Agent as a prerequisite for FDA registration. While this is a clear requirement, what d...
With the EU Medical Device Regulation (MDR) establishing the critical role of the Person Responsible for Regulatory Compliance (PRRC), many manufacturers—particularly small and medium-sized enterprise...
For a company developing a novel Software as a Medical Device (SaMD) intended for both diagnostic screening and pharmacogenetic assessment, what are the key considerations for determining the appropri...
With the Carbon Border Adjustment Mechanism (CBAM) transitional period underway and full implementation approaching, non-EU operators in affected sectors must appoint an authorized representative to m...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities are now required to designate a U.S. Agent to serve as the primary point of communication ...
Given the critical role of the Person Responsible for Regulatory Compliance (PRRC) under the EU MDR, and with regulatory bodies issuing updated guidance on Post-Market Surveillance and Vigilance (PMSV...
When a non-EU manufacturer plans for the upcoming REACH registration deadlines, such as the one in 2026, a key budgetary question is the cost of securing an Only Representative (OR). However, a simple...
Given the significant French VAT reforms anticipated for 2026, including the end of customs procedure 42 which will mandate a fiscal representative for many non-EU businesses, what comprehensive frame...